The shadow of generic challenges has repeatedly loomed around copyright’s blockbuster drug, Viagra, sparking questions about the outlook of related pharmaceutical stakes. While first periods saw impressive profits, the intellectual property expiration has allowed the way for discounted copies, possibly reducing earnings and presenting a real dang